Related Experiment Video
Updated: May 22, 2025

Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
AI model for predicting asthma prognosis in children
Elham Sagheb1, Chung-Il Wi2, Katherine S King3
1Department of Artificial Intelligence and Informatics, Mayo Clinic, Rochester, Minn.
Background:
Childhood asthma often continues into adulthood, but some children experience remission. Utilizing electronic health records (EHRs) to predict asthma prognosis can aid health care providers and patients in developing effective prioritized care plans.
Objective:
We aimed to develop artificial intelligence (AI) models using various clinical variables extracted from EHRs to predict childhood asthma prognosis (remission vs no remission) in different age groups.
Methods:
We developed AI models utilizing patients' EHRs during the first 6, 9, or 12 years of their lives to predict their asthma prognosis status at ages 6 to 9, 9 to 12, or 12 to 15 years, respectively. We first developed the models based on a manually annotated birth cohort (n = 900). We then leveraged a larger birth cohort (n = 29,594) labeled automatically (with weak labels) by a previously validated natural language processing algorithm for asthma prognosis. Different models (logistic regression, random forest, and XGBoost [eXtreme Gradient Boosting]) were tested with diverse clinical variables from structured and unstructured EHRs.
Results:
The best AI models of each age group produced a prediction performance with areas under the receiver operating characteristic curve ranging from 0.85 to 0.93. The prediction model at age 12 showed the highest performance. Most of the AI models with weak labels showed enhanced performance, and models using the top 10 variables performed similarly to those using all of the variables.
Conclusions:
The AI models effectively predicted asthma prognosis for children by using EHRs with a relatively small number of variables. This approach demonstrates the potential to enhance prioritized care plans and patient education, improving disease management and quality of life for asthmatic patients.
More Related Videos
05:31Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
09:58A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
Related Concept Videos
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma-I: Introduction
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Lung Capacity
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...